

2025 CJD Foundation Family Conference, July 11 – 13, 2025

Evaluation Form

Thank you for attending the CJD Foundation Family Conference. Your feedback is very important to us. Please take a few minutes to fill out this evaluation form and return it to a CJD Foundation staff member or email it to help@cjd.foundation.org.

Scale: 5 – *EXCELLENT* 4 – *VERY GOOD* 3 – *GOOD* 2 – *FAIR* 1 – *POOR*

Venue and Resources

Venue	5	4	3	2	1
Catering	5	4	3	2	1
Print Resources	5	4	3	2	1
Portal	5	4	3	2	1

Comments on Venue and Resources: _____

Friday Programs

Brian Appleby, MD, and Lori Nusbaum, Sporadic Prion Disease Meeting	5	4	3	2	1	N/A
Debbie Yobs, Family Panel, and Expert Resources, Genetic Prion Disease Meeting	5	4	3	2	1	N/A
Brian Appleby, MD, Prion Disease Basics – Clinical	5	4	3	2	1	N/A
Joel Watts, PhD, Prion Research Basics – Research	5	4	3	2	1	N/A
Tessa Garcia McEwen, AM, LCSW, DCCS, CDP, Bereavement Workshop	5	4	3	2	1	N/A

Comments on Friday Programs: _____

Saturday Programs

Glenn Telling, PhD, Keynote Address: Novel Mouse Models of Prion Diseases	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Research Grant Recipient Reports, Group A, Moderator: Joel Watts, PhD:

Elena De Cecco, PhD, “Investigation of Glycoprotein Nonmetastatic Melanoma protein B (GPNMB) as potential therapeutic target in Prion Diseases”	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Qingzhong Kong, PhD, “Development of ADAM8-based Gene Therapy for CJD”	5	4	3	2	1	N/A
---	---	---	---	---	---	-----

Surabhi Mehra, PhD, MSc, (virtual) “Understanding the molecular mechanism of spontaneous prion emergence in knock-in mouse models”	5	4	3	2	1	N/A
---	---	---	---	---	---	-----

Gerold Schmitt-Ulms, PhD, (virtual) “Bridging the pre-clinical gap for a small brain-penetrant molecule that reduces PrPC levels”	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Research Grant Recipient Report, Group A Debrief	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Research Grant Recipient Reports, Group B, Moderator: Richard Knight, BA, BM BCh, FRCP(E):

Joaquín Castilla, PhD, (virtual), “Exploring the efficacy of dominant negative protein-based gene therapy for different prion diseases: in vivo proof-of-concept study”	5	4	3	2	1	N/A
---	---	---	---	---	---	-----

Arielle Hay, PhD, “Generating cerebral organoids from donors with sporadic Creutzfeldt-Jakob Disease”	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Matthias Schmitz, PhD, “Validation of a non-invasive diagnostic test for prion diseases using tear fluid”	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Research Grant Recipient Report, Group B Debrief	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

James Mastrianni, MD, PhD, A Multi-Targeted Approach in Search of Prion Disease Therapy	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Moving Roundtables	5	4	3	2	1	N/A
--------------------	---	---	---	---	---	-----

Comments on Saturday Programs:

Sunday Programs

Debbie Yobs and Joel Watts, PhD, CJD Foundation Grants Program	5	4	3	2	1	N/A
---	---	---	---	---	---	-----

Brian Appleby, MD, Eriton Cunha, PhD, Katie Glisic, MA, Meghan Lewis, MA, National Prion Disease Pathology Surveillance Center Panel	5	4	3	2	1	N/A
---	---	---	---	---	---	-----

Ryan Maddox, PhD, 2025 Centers for Disease Control and Prevention Report	5	4	3	2	1	N/A
---	---	---	---	---	---	-----

Debbie Yobs, Karen Adams, Pat Elliot, Elizabeth Rodriguez, Tim Schwister, CJD Foundation Family Panel: "My Story, My Mission"	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Kiyoshi Arita, MSc, Elizabeth McNeil, MD, MSc, Eric Minikel, PhD, Nina Oberbeck, PhD, Anne Smith, PhD, Drug Development Panel	5	4	3	2	1	N/A
--	---	---	---	---	---	-----

Comments on Sunday Programs:

Why Attend Conference

Please rate how much of a factor each of the following was in choosing to attend Conference, 5 meaning it was a significant factor in choosing to attend and 1 meaning it was not a significant factor in choosing to attend.

Location	5	4	3	2	1	N/A
----------	---	---	---	---	---	-----

Speakers/Agenda	5	4	3	2	1	N/A
-----------------	---	---	---	---	---	-----

Cost	5	4	3	2	1	N/A
------	---	---	---	---	---	-----

Other (please specify) _____	5	4	3	2	1	N/A
------------------------------	---	---	---	---	---	-----

If location factored into your decision to attend Conference, please explain.

If speakers or agenda, which factored into your decision to attend Conference? Please explain.

This image shows a blank sheet of white paper with horizontal ruling lines. The lines are evenly spaced and extend across the width of the page. There are no margins, text, or other markings on the paper.

NAME: _____